Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.780
0.00 (0.00%)
Sep 12, 2025, 9:47 AM EDT - Market open
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$647,499
Market Cap
11.91M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16 | 1 | 6.67% |
Dec 31, 2023 | 15 | 0 | - |
Dec 31, 2022 | 15 | 0 | - |
Dec 31, 2021 | 15 | -3 | -16.67% |
Dec 31, 2020 | 18 | 2 | 12.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SNGX News
- 8 days ago - Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses - PRNewsWire
- 10 days ago - Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 24 days ago - Why Is Soligenix Stock Soaring On Monday? - Benzinga
- 25 days ago - FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results - PRNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - PRNewsWire
- 5 weeks ago - NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewsWire
- 6 weeks ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - PRNewsWire
- 2 months ago - Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PRNewsWire